In the tightly regulated architecture of the human cell nucleus, telomeres and centromeres are supposed to be strangers. They occupy distinct territories, performing separate, essential roles in maintaining genomic stability. But in a subset of aggressive, hard-to-treat cancers, that separation breaks down in a way that defies biological convention.

Researchers at the University of Pittsburgh have discovered that cancers relying on the alternative lengthening of telomeres (ALT) pathway are actively hijacking centromeric DNA and chromatin components, incorporating them directly into their telomeres. This "bizarre and unique event," as described by the study’s senior author, Roderick O’Sullivan, PhD, provides a survival mechanism that allows these tumors to maintain their telomere integrity and continue their rapid, unchecked growth.

The Breakdown of Genomic Boundaries

ALT is a specialized telomere maintenance mechanism used by roughly 5% to 10% of all cancers, including aggressive forms of sarcomas, gliomas, and pancreatic neuroendocrine tumors. While most tumors reactivate the enzyme telomerase to achieve immortality, ALT-positive cancers rely on recombination-based mechanisms.

For years, the scientific consensus held that ALT was a process of telomeres recombining with other telomeres. The new study, published in Nature, upends that assumption. By analyzing ALT-positive cancer cell lines and primary pediatric neuroblastoma samples, the team found that centromeric DNA repeats are being inserted into telomeric regions.

"Centromeres and telomeres typically occupy exclusive nuclear territories," said co-corresponding author Yael Nechemia-Arbely, PhD. "When we first saw the results, I was very skeptical. It took a long time and a lot of quantification and looking at it from many different angles to convince us that this was real."

The Role of ATRX Loss

The researchers traced this phenomenon to the loss of ATRX, a chromatin-remodeling protein that is frequently mutated in ALT-positive cancers. ATRX loss has long been used as a clinical biomarker for ALT status, but its specific role in this genomic rearrangement was previously unclear.

According to the study, the loss of ATRX destabilizes both telomeres and centromeres simultaneously. In a healthy cell, these regions are protected and spatially separated. Without ATRX, these domains become exposed, enabling an interaction that should never occur.

"Now you have these two exposed domains that either through chance or necessity are interacting, and the ultimate byproduct of that transaction is the insertion of DNA repeats from the centromere into the telomere," O’Sullivan explained.

Not Just a Byproduct: A Functional Adaptation

Perhaps the most significant finding is that this centromeric material is not merely a passive byproduct of a chaotic genome. Functional experiments revealed that the integrated centromeric chromatin is actively recruited to help the cancer cell survive.

When the researchers disrupted the deposition of CENP-A—a protein essential for centromere function—they found that telomere integrity was compromised and ALT activity was impaired. This suggests that the cancer cells have adapted to use these hijacked centromeric components as a scaffold for their own survival machinery.

What Experts Say

"For a long time, the field viewed ALT as telomeres recombining with other telomeres," said co-corresponding author Ragini Bhargava, PhD. "What this study is showing is that when you lose ATRX, telomeres become prone not only to recombination within telomeres but also with other parts of the genome. One of those regions is the centromere, which should be highly protected and spatially very far away from telomeres."

Key Takeaways

  • ALT-positive cancers, which account for 5% to 10% of tumors, have been found to incorporate centromeric DNA into their telomeres to maintain stability.
  • The mechanism is driven by the loss of the ATRX protein, which normally keeps telomeres and centromeres in separate nuclear territories.
  • The hijacked centromeric material is functionally integrated, suggesting that these cancers have evolved a unique, previously unrecognized form of interchromosomal communication to survive.

Future Implications

The discovery of this survival mechanism opens a new window into the vulnerabilities of ALT-positive tumors. By identifying the specific machinery that allows these cancers to integrate centromeric material, researchers may eventually be able to develop therapies that target this process, effectively stripping the cancer of its ability to protect its telomeres.

As the team continues to map the consequences of this genomic "hijack," the next phase of research will focus on whether these centromeric signatures can be used as more precise diagnostic markers or if they represent a specific point of failure that can be exploited in the clinic.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.